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ADHD medications only during the school year and stop treat-
ment in the summer months. Assuming that a child meets the
DSM-IV-TR criteria for ADHD, taking him/her off treatment,
even outside the school setting, could impair his/her ability to
function in everyday life. At the same time, it provides the child
with a holiday from potentially serious side effects associated
with stimulant use. Further research is needed to compare these
and other beneﬁts/risks associated with discontinuing ADHD
therapy during the summer months.
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OBJECTIVE: To assess the impact of prior medication use and
comorbidities on treatment initiation with duloxetine vs. ven-
lafaxine XR for patients with major depression disorder (MDD)
using retrospective claims data. METHODS: Using the PharMet-
rics Database, we studied commercially insured individuals aged
18–64 who initiated treatment with duloxetine or venlafaxine
XR between July 2005 and July 2006, and had 1 prior diag-
nosis with MDD and continuous enrollment during 12 months
prior to initiation date. Initiation was deﬁned as the ﬁrst use of a
medication preceded by three months without a prescription of
the same medication. Chi-square and Logistic regression analysis
of patients’ demographics, past-year medication use and comor-
bidities assessed predictors of initiations with duloxetine vs.
venlafaxine XR. RESULTS: A total of 12,662 patients (73.8%
female) initiated treatment with duloxetine, and 14,801 (72.1%
female) with venlafaxine XR. Compared to venlafaxine XR
patients, signiﬁcantly more duloxetine patients received 3
unique antidepressants (39.5% vs. 25.2%), 3 unique pain
medications (25.8% vs. 15.1%), SSRIs (55.5% vs. 41.2%),
TCAs (12.5% vs. 7.5%), analgesics (63.6% vs. 51.6%), anticon-
vulsants (31.3% vs. 19.2%), or hypnotics (31.5% vs. 22.0%),
and had 8 unique co-morbid medical conditions (38.8% vs.
29.5%) and diagnoses with pain (76.4% vs. 67.1%) (all p-values
<0.001). Regression results revealed that the signiﬁcant factors
for duloxetine initiation vs. venlafaxine XR were prior use of 3
unique antidepressants (OR = 1.34), 3 unique pain medi-
cations (OR = 1.24), SSRIs (OR = 1.51), TCAs (OR = 1.19),
analgesics (OR = 1.12), anticonvulsants (OR = 1.45), hypno-
tics (OR = 1.25), and prior medical comorbidities of pain
(OR = 1.11) (all p-values <0.001). CONCLUSION: The results
suggest that duloxetine patients with MDD are more likely to
have more medical conditions and complex prior medication
treatments than venlafaxine XR patients.
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OBJECTIVE: This study examined the health service utilization
and treatment costs among depression patients who received
antidepressant medication, psychotherapy or both. METHODS:
This study used medical and pharmacy claims data from 220,620
employees from three employer groups from September 2002 to
December 2003. Depression patients (n = 4653) were identiﬁed
using ICD-9 diagnosis codes from medical claims data. Differ-
ences in treatment costs and comorbid conditions were examined
between depression patients who received psychotherapy and
those who did not. RESULTS: Among eligible members, 4,653
(2.1%) had a primary diagnosis of depression. Nearly 70% were
female with an average age of 39.7 years. Approximately half of
the depression patients (46.9%) received antidepressant medica-
tion alone while 34.2% of patients received both psychotherapy
and medication. Only 19.3% of depression patients received
psychotherapy without medications. The average total treatment
cost for depression patients who received both psychotherapy
and medications was $10,565, while the average treatment cost
for patients who only used medication was $10,014. These treat-
ment costs were not signiﬁcantly different. The average treatment
cost for psychotherapy alone was $3,945. The most frequent
comorbid conditions among depression patients were muscu-
loskeletal and chronic pain (29.9%), anxiety (26.6%), injuries
(18.7%), hypertension (14.4%), asthma (6.5%), diabetes
(6.1%), arthritis (5.4%), urinary tract infection (4.4%) and drug
dependence and alcohol abuse (4.1%). Depression patients who
received both medication and psychotherapy had signiﬁcantly
more comorbid anxiety (33.1%) and drug and alcohol abuse
(5.8%) than those who received medications or psychotherapy
alone (p < 0.001). CONCLUSION: Depression patients who
used psychotherapy including antidepressant medications did
not have signiﬁcantly different health care costs than depression
patients who did not receive psychotherapy treatments. Depres-
sion patients with comorbid psychological conditions such as
anxiety or drug abuse were more likely to receive psychotherapy
treatment (p < 0.001).
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OBJECTIVE: Those with BPD often present when depressed
leading to potential misdiagnosed and treatment as depression,
particularly in primary care. Inappropriate treatment increases
risk for suicide and rapid cycling. STABLE was initiated to
develop and ﬁeld test evidence-based clinical performance mea-
sures (PM) for endorsment by the National Quality Forum, and
eventual implementation for quality improvement. METHODS:
An expert panel used a validated method to develop 15 perfor-
mance measures for BPD and depression. Field testing was
conducted on 802 medical records among 80 practices (48 psy-
chiatry, 32 primary care) in 28 states. Feasibility was evaluated
using standard parameters with inter-rater reliability evaluated
in a subset of records (proportion agreement and kappa).
RESULTS: Fifteen measures were developed and validated in
four domains: initial assessment, appropriate pharmacotherapy,
adjunctive treatment, monitoring treatment response and
antipsychotic-related metabolic changes. A total of 802 cases
(419 BPD; 383 depression) were audited. In those with depres-
sive symptoms, primary care and specialists assessed patients
for mania or family history of mental health disorders in only
47.6% and 40.8%, respectively. Suicide risk assessment was
only conducted in 71.5% of patients, and substance abuse
assessment in only 60.5%. For BPD speciﬁc measures, results
indicated adequate assessment of functional status at baseline
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and within 12 weeks of treatmet of only 41.4%. Appropriate
psychosocial interventions were recommended in only 39.9%,
condition education in 33.4%, assessment for hyperglycemia
after initiation an atypical antipsychotic in 19.7% and weight
measurement in 15.5%) Psychiatric practices performed better
than primary care on most measures. A subset of patients were
double abstracted and demonstrated substantial simple agree-
ment ranging from 89.5% to 100% and kappa from 0.75 to
1.0. CONCLUSION: The need to improve quality of care for
individuals with bipolar disorder is signiﬁcant. These PM can
be implemented using chart audits and be a useful component
of quality improvement efforts.
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To introduce, deﬁne and differentiate between conceptual
models, endpoint models and conceptual frameworks, and to
discuss how they ﬁt together in the context of supporting product
claims in drug development. In addition, to explore the added
beneﬁt of including health economic concepts and endpoints
within the same framework. Using alcohol dependence (AD)
as an illustrative example, a conceptual model, hypothetical
endpoint model and conceptual framework (for a selected
AD-speciﬁc PRO measure) were developed, following the newly
issued guidance from the FDA relating to label claims. The
potential for combining each of these elements together with
related documents, such as the Target Product Proﬁle to support
a product claim, was assessed as was the feasibility of including
health economic claims within a similar framework. The devel-
opment of a holistic framework to support not only label claims,
but also value claims is presented. The framework develops the
recent guidance by the FDA for PROs and suggests that it may be
possible to include health economic outcomes within the general
framework. Doing so offers potential beneﬁts in relation to
applying the same rigorous treatment now required for PROs,
encourages genuine collaboration between different stakeholders
and provides a framework for communicating value concepts
outside the discipline of outcomes research. In particular, clear
speciﬁcation of health economic outcomes within an endpoint
model may assist with the design of prospective studies. Never-
theless, it is clear that value claims remain the responsibility of
reimbursement authorities rather than regulators. Each of the
models discussed are useful in supporting product claims in drug
development and, from a PRO perspective, endpoint models and
conceptual frameworks are essential. From a health economics
perspective, employing a similar framework encourages scientiﬁc
rigour, facilitates communication and could help design of appro-
priate data collection in clinical trials.
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OBJECTIVE: Evaluate the prevalence and costs of
co-morbidities in employees with/without multiple sclerosis
(MS). METHODS: A United States employee health care claims
database from 2001–2007 was used to identify subjects with
MS (ICD-9 code = 340.XX) and a control cohort without MS.
The control group was matched 20:1 to the MS subjects on
demographics, job-information, geography, and Charlson Co-
morbidity Index. Based on ICD-9 codes, direct medical costs
associated with the Agency for Health care Research and Quality
17 Major and 261 Speciﬁc Diagnostic Categories (MDCs and
SCs) were identiﬁed. Index dates for the MS cohort were the
diagnosis or therapy initiation date, and for Controls the average
MS date. The 12-month post-index date utilization and costs
were analyzed. Prevalence comparisons were tested using
z-scores of log odds ratios and cohort cost comparisons using
t-tests (P < 0.05). RESULTS: A total of 765 employees with MS
and 15,300 matched controls were analyzed. The MS cohort had
signiﬁcantly higher prevalence of 15/17 MDCs and were sig-
niﬁcantly costlier in 7. The top more prevalent MDCs were:
Nervous System+Sense Organs, Musculo Connective Tissue,
and “Other Conditions” which had 53.4%, 18.2% and 17.1%
higher prevalence, respectively and were $1837, $256, and $241
more costly, respectively. However, it was surprising to see the
prevalence and higher cost of conditions like: Circulatory System
(31.1%–21.9%; $568–$235) Mental Disorders (20.7%–11.6%;
$147–$61) Digestive System (23.9%–16.2%; $369–$193); Skin
& Subcutaneous Tissue (25.4%–19.7%; $129–$69). Evaluating
these using the “speciﬁc categories”, signiﬁcantly higher preva-
lence and costs were reported among the MS cohort in: other
nervous system disorders, headache and migraine, epilepsy con-
vulsions, blindness and vision defects, dizziness/vertigo, other
mental conditions. CONCLUSION: Employees with MS have
more prevalent co-morbid conditions than subjects without MS.
From an insurer’s perspective, this increased burden for MS
sufferers is also associated with higher costs.
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OBJECTIVES: To analyse how the development of an industry-
sponsored, but physician directed, multinational database has
facilitated collection and interpretation of serial clinical and
laboratory observations on patients with Fabry disease—a rare
lysosomal storage disorder caused by deﬁciency of the enzyme
a-galactosidase A. METHODS: In 2001, physicians established
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